Victoria Gershuni1, Yun R Li1,2, Austin D Williams1, Alycia So1, Laura Steel1, Elena Carrigan1, Julia Tchou3. 1. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th Floor South, Philadelphia, PA, 19104, USA. 2. Internal Medicine Residency Program, Department of Medicine, Eisenhower Medical Center, Rancho Mirage, CA, USA. 3. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th Floor South, Philadelphia, PA, 19104, USA. julia.tchou@uphs.upenn.edu.
Abstract
PURPOSE: Obesity is associated with tumor promoting pathways related to insulin resistance and chronic low-grade inflammation which have been linked to various disease states, including cancer. Many studies have focused on the relationship between obesity and increased estrogen production, which contributes to the pathogenesis of estrogen receptor-positive breast cancers. The link between obesity and other breast cancer subtypes, such as triple-negative breast cancer (TNBC) and Her2/neu+ (Her2+) breast cancer, is less clear. We hypothesize that obesity may be associated with the pathogenesis of specific breast cancer subtypes resulting in a different subtype distribution than normal weight women. METHODS: A single-institution, retrospective analysis of tumor characteristics of 848 patients diagnosed with primary operable breast cancer between 2000 and 2013 was performed to evaluate the association between BMI and clinical outcome. Patients were grouped based on their BMI at time of diagnosis stratified into three subgroups: normal weight (BMI = 18-24.9), overweight (BMI = 25-29.9), and obese (BMI > 30). The distribution of breast cancer subtypes across the three BMI subgroups was compared. RESULTS: Obese and overweight women were more likely to present with TNBC and normal weight women with Her2+ breast cancer (p = 0.008). CONCLUSIONS: We demonstrated, for the first time, that breast cancer subtype distribution varied significantly according to BMI status. Our results suggested that obesity might activate molecular pathways other than the well-known obesity/estrogen circuit in the pathogenesis of breast cancer. Future studies are needed to understand the molecular mechanisms that drive the variation in subtype distribution across BMI subgroups.
PURPOSE:Obesity is associated with tumor promoting pathways related to insulin resistance and chronic low-grade inflammation which have been linked to various disease states, including cancer. Many studies have focused on the relationship between obesity and increased estrogen production, which contributes to the pathogenesis of estrogen receptor-positive breast cancers. The link between obesity and other breast cancer subtypes, such as triple-negative breast cancer (TNBC) and Her2/neu+ (Her2+) breast cancer, is less clear. We hypothesize that obesity may be associated with the pathogenesis of specific breast cancer subtypes resulting in a different subtype distribution than normal weight women. METHODS: A single-institution, retrospective analysis of tumor characteristics of 848 patients diagnosed with primary operable breast cancer between 2000 and 2013 was performed to evaluate the association between BMI and clinical outcome. Patients were grouped based on their BMI at time of diagnosis stratified into three subgroups: normal weight (BMI = 18-24.9), overweight (BMI = 25-29.9), and obese (BMI > 30). The distribution of breast cancer subtypes across the three BMI subgroups was compared. RESULTS:Obese and overweight women were more likely to present with TNBC and normal weight women with Her2+ breast cancer (p = 0.008). CONCLUSIONS: We demonstrated, for the first time, that breast cancer subtype distribution varied significantly according to BMI status. Our results suggested that obesity might activate molecular pathways other than the well-known obesity/estrogen circuit in the pathogenesis of breast cancer. Future studies are needed to understand the molecular mechanisms that drive the variation in subtype distribution across BMI subgroups.
Entities:
Keywords:
Breast cancer; Breast cancer subtype; Her2+ breast cancer; Obesity; Overweight; TNBC
Authors: Ainhoa Arana Echarri; Mark Beresford; John P Campbell; Robert H Jones; Rachel Butler; Kenneth J Gollob; Patricia C Brum; Dylan Thompson; James E Turner Journal: Front Immunol Date: 2021-02-01 Impact factor: 7.561
Authors: Ugonna Ihenacho; Ann S Hamilton; Wendy J Mack; Anna H Wu; Jennifer B Unger; Dorothy R Pathak; Kelly A Hirko; Richard T Houang; Michael F Press; Kendra L Schwartz; Lydia R Marcus; Ellen M Velie Journal: Breast Cancer Res Treat Date: 2022-08-04 Impact factor: 4.624
Authors: Laura Burkbauer; Macy Goldbach; Cassie Huang; Julia Lewandowski; Robert Krouse; Kelly Allison; Julia Tchou Journal: Breast Cancer Res Treat Date: 2022-06-25 Impact factor: 4.624
Authors: Zhoufeng Ye; Shuai Li; Gillian S Dite; Tuong L Nguyen; Robert J MacInnis; Irene L Andrulis; Saundra S Buys; Mary B Daly; Esther M John; Allison W Kurian; Jeanine M Genkinger; Wendy K Chung; Kelly-Anne Phillips; Heather Thorne; Ingrid M Winship; Roger L Milne; Pierre-Antoine Dugué; Melissa C Southey; Graham G Giles; Mary Beth Terry; John L Hopper Journal: Cancer Prev Res (Phila) Date: 2022-03-01
Authors: Bin Bao; Emily A Teslow; Cristina Mitrea; Julie L Boerner; Greg Dyson; Aliccia Bollig-Fischer Journal: Mol Cancer Res Date: 2020-09-10 Impact factor: 5.852
Authors: Emily A Teslow; Cristina Mitrea; Bin Bao; Ramzi M Mohammad; Lisa A Polin; Greg Dyson; Kristen S Purrington; Aliccia Bollig-Fischer Journal: Mol Oncol Date: 2019-03-01 Impact factor: 6.603
Authors: Trygve Lofterød; Elin S Mortensen; Hawa Nalwoga; Tom Wilsgaard; Hanne Frydenberg; Terje Risberg; Anne Elise Eggen; Anne McTiernan; Sura Aziz; Erik A Wist; Andreas Stensvold; Jon B Reitan; Lars A Akslen; Inger Thune Journal: BMC Cancer Date: 2018-06-15 Impact factor: 4.430